{"id":"W2746282229","doi":"10.1200/jco.2017.35.15_suppl.e20503","title":"Brigatinib (BRG) in crizotinib (CRZ)-refractory ALK+ non-small cell lung cancer (NSCLC): Updates from ALTA, a pivotal randomized phase 2 trial.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lung Cancer Treatments and Mutations","field":"Medicine","cited_by":4,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre","funders":"","keywords":"Medicine; Clinical endpoint; Internal medicine; Gastroenterology; Adverse effect; Crizotinib; Refractory (planetary science); Nausea; Lung cancer; Ceritinib; Vomiting; Phases of clinical research; Surgery; Randomized controlled trial; Clinical trial","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001949225,0.0007260875,0.001060416,0.000412305,0.0002419321,0.0006423276,0.0006035261,0.0006797318,0.004764949],"category_scores_gemma":[0.001102273,0.0002995572,0.0007120459,0.0004775636,0.0003032263,0.0005056539,0.0003103497,0.001827436,0.0008194739],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0005591018,"about_ca_system_score_gemma":0.0008203018,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.00081471,"about_ca_topic_score_gemma":0.004186208,"domain_scores_codex":[0.9995773,0.000238969,0.00003137621,0.00003980322,0.00006253702,0.00005004141],"domain_scores_gemma":[0.9995735,0.00008560982,0.0001345172,0.00002082852,0.00002971929,0.0001558649],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"randomized_trial","study_design_scores_codex":[0.6007736,0.01042863,0.009196188,0.003516913,0.001815829,0.0002913429,0.0001803104,0.001389274,0.01913105,0.0005847931,0.02809243,0.3245997],"study_design_scores_gemma":[0.8402739,0.1087361,0.02690046,0.0003394347,0.001352495,0.0006096247,0.00006039309,0.0008306657,0.002118279,0.0003646733,0.01837881,0.00003522832],"study_design_candidate":"randomized_trial","study_design_consensus":"randomized_trial","genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.908602,0.06401464,0.0009492344,0.004301142,0.0005873257,0.004850537,0.006937791,0.0002987407,0.009458683],"genre_scores_gemma":[0.9519783,0.02405636,0.002631494,0.003730996,0.0004781648,0.003663543,0.009736693,0.0000490984,0.003675434],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004764949,"threshold_uncertainty_score":0.01594031,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.07764790315109184,"score_gpt":0.5180193048804581,"score_spread":0.4403714017293663,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}